RBC Capital analyst Conor McNamara maintained a Buy rating on OmniAb (OABI – Research Report) yesterday and set a price target of $7.00. The company’s shares closed yesterday at $4.57.
According to TipRanks, McNamara is an analyst with an average return of -8.5% and a 37.00% success rate. McNamara covers the Healthcare sector, focusing on stocks such as QuidelOrtho, Maravai Lifesciences Holdings, and Bio-Rad Laboratories.
OmniAb has an analyst consensus of Strong Buy, with a price target consensus of $9.67, which is an 111.60% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $11.00 price target.
The company has a one-year high of $6.72 and a one-year low of $3.14. Currently, OmniAb has an average volume of 512.3K.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OABI in relation to earlier this year. Most recently, in March 2024, Matthew W. Foehr, the President & CEO of OABI bought 243,613.00 shares for a total of $907,023.21.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OmniAb (OABI) Company Description:
Avista Public Acquisition Corp II is a blank check company.
